Evidence map›Paper›PMID 34736479›Full record

Observational studyHealth and quality of life outcomes2021

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study.

Mia Sommer, Lene Kongsgaard Nielsen, Lars Børty Nielsen, Rasmus Froberg Brøndum, Marlene Maria Nielsen, Anne Stoffersen Rytter, Charles Vesteghem, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Martin Bøgsted and 2 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mia SommerDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark. miso@ucn.dk.ORCID http://orcid.org/0000-0002-9761-6201
Lene Kongsgaard NielsenQuality of Life Research Centre, Department of Hematology, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0003-2083-3870
Lars Børty NielsenDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Rasmus Froberg BrøndumDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Marlene Maria NielsenDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Anne Stoffersen RytterDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Charles VesteghemDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Marianne Tang SeverinsenDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Tarec Christoffer El-GalalyDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Martin BøgstedDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Mette GrønkjærClinical Nursing Research Unit, Aalborg University Hospital, Aalborg, Denmark.
Lone JørgensenClinical Nursing Research Unit, Aalborg University Hospital, Aalborg, Denmark.
Aalborg University Hospital · DK

Funding

Novo Nordisk Fonden NNF17OC0028936
6 · The paper itself

Abstract

backgroundPatients with hematological cancer who experience relapse or progressive disease often face yet another line of treatment and continued mortality risk that could increase their physical and emotional trauma and worsen their health-related quality of life. Healthcare professionals who use patient-reported outcomes to identify who will have specific sensitivities in particular health-related quality of life domains may be able to individualize and target treatment and supportive care, both features of precision medicine. Here, in a cohort of patients with relapsed or progressive hematological cancer, we sought to identify health-related quality of life domains in which they experienced deterioration after relapse treatment and to investigate health-related quality of life patterns.

methodPatients were recruited in connection with a precision medicine study at the Department of Hematology, Aalborg University Hospital. They completed the European Organization for Research and Treatment of Cancer questionnaire and the Hospital Anxiety and Depression Scale at baseline and at 3, 6, 9, and 12 months after the relapse diagnosis or progressive cancer. Modes of completion were electronically or on paper. Clinically relevant changes from baseline to 12 months were interpreted according to Cocks' guidelines. We quantified the number of patients with moderate or severe symptoms and functional problems and the number who experienced improvements or deterioration from baseline to 12 months.

resultsA total of 104 patients were included, of whom 90 (87%) completed baseline questionnaires and 50 (56%) completed the 12-month assessments. The three symptoms that patients most often reported as deteriorating were fatigue (18%), insomnia (18%), and diarrhea (18%). The three functions that patients most often reported as deteriorating were role (16%) and emotional (16%) and cognitive (16%) functioning.

conclusionIn this study, patient-reported outcome data were useful for identifying negatively affected health-related quality of life domains in patients with relapsed or progressive hematological cancer. We identified patients experiencing deterioration in health-related quality of life during treatment and characterized a potential role for patient-reported outcomes in precision medicine to target treatment and supportive care in this patient group.

Indexed as

Neoplasm Recurrence, LocalQuality of LifeFatigueHumansPatient Reported Outcome MeasuresSurveys and QuestionnairesHealth-related quality of lifeHematological cancerPatient-reported outcomePrecision medicineRelapse

Identifiers

PMID34736479
PMCPMC8567661
OpenAlexW3208067889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.